mutation/amplification de KDR (VEGFR2) — récepteur du facteur de croissance endothélial vasculaire 2
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BIO-KDR |
|---|---|
| Type | Biomarqueur |
| Alias | KDR / mutation VEGFR2Мутація / ампліфікація KDR (VEGFR2) — рецептор судинного ендотеліального фактора росту 2 |
| État | reviewed 2026-05-04 | pending_clinical_signoff |
| Maladies | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Données biomarqueurs
| Type de biomarqueur | gene_mutation |
|---|---|
| Détails de la mutation | {"exon": "multiple; domaine kinase (V297I, T771A, Q472H) et domaine extracellulaire", "functional_impact":"gain de fonction (activation autonome VEGFR2 → PI3K/AKT, MAPK, PLCγ → angiogenèse, survie)", "gene": «KDR», "variant_type": „activation du missense; amplification (rare)"} |
| Mesure | MéthodeTumor NGS panel (DNA); IHC (not routinely used for mutation detection); FISH for amplification |
| Recherche de la faisabilité | {"gene": "KDR", "variant": "activating_mutation"} |
| Biomarqueurs connexes | BIO-VEGFA BIO-FGFR1 BIO-PDGFRA |
Notes
KDR encodes VEGFR2 (Vascular Endothelial Growth Factor Receptor 2), the primary mediator of VEGF-driven tumor angiogenesis. Somatic KDR activating mutations occur in ~2–3% of NSCLC (mixed histologies) and ~1–2% across multiple other solid tumors. Multiple approved multi-target TKIs inhibit VEGFR2 (ramucirumab, lenvatinib, cabozantinib, regorafenib, sunitinib, sorafenib), but none are approved in a KDR mutation-selected indication. In NSCLC, ramucirumab + docetaxel (REVEL, FDA 2014) is approved for 2L regardless of KDR status. KDR mutation has been hypothesized to predict response to VEGFR-targeted agents, but prospective evidence is lacking; no companion diagnostic exists. Clinical significance: investigational target; KDR mutation is reported on NGS panels but does not currently change standard therapy selection in NSCLC.
Utilisé par
Pertinence thérapeutique
BMA-KDR-NSCLC- KDR (VEGFR2) somatic activating mutations occur in ~2–3% of NSCLC across histologies. KDR...